R&D SERVICES
A Pharma Consulting Co.

DR. THOMAS N. THOMPSON WWW.RDSERVKC.COM

PRESIDENT AND PRINCIPAL CONSULTANT
tnt@rdservkc.com

CURRICULUM VITAE

OBJECTIVE

A technical consulting opportunity that utilizes my 31 years experience in pharmaceutical drug development, project management, laboratory research, business development, and technical presentation skills.

SUMMARY OF QUALIFICATIONS

Proven track record in pharmaceutical consulting, business development/client interface, laboratory research, and in managing projects, people, and technical teams, Unique technical experience spans the areas of medicinal chemistry, drug metabolism, pharmacokinetics, biochemical toxicology and pharmaceutics. Participation on multi-disciplinary team provided breadth of knowledge across pharmaceutical R&D functions such as drug discovery support, drug metabolism, pharmacokinetics, clinical research, regulatory, QA, formulations, and bioanalytical method development and sample analysis. Sound organizational and interpersonal skills have been developed and utilized in both small and large technical group supervision. Specific areas of expertise include:

- Preclinical and early clinical drug development
- Project management, study design, placement and monitoring
- Business development (including preparation of marketing materials, external client presentations/ interactions
- Quality Assurance (SOP preparation and review, maintenance of GLP compliant lab)
- Technical writing, reviewing and editing (project reports, manuscripts, review articles, book chapters)
- Technical laboratory management (responsible for up to 30 associates)
- Regulatory Affairs (authored IND/NDA/CTD sections, investigator brochure and package labeling inserts)
- Oral technical presentations (15 invited platform presentations over past 8 years)
- Expertise in technical literature searches and preparation of position papers
- Multi-disciplinary project team experience
- Animal and Human ADME
- Animal and human pharmacokinetics
- In vivo and in vitro biotransformation
- Assessmet of drug interaction potential based on in vitro enzyme mapping, drug induction and inhibition studies
- In vitro early ADME (absorption, CNS permeation, metabolic stability
- Bioanalytical method development and sample analysis
- Formulation development and support

R&D SERVICES
A Pharma Consulting Co.

DR. THOMAS N. THOMPSON WWW.RDSERVKC.COM

PRESIDENT AND PRINCIPAL CONSULTANT
tnt@rdservkc.com

CURRICULUM VITAE

EDUCATION

Postdoctoral Fellowship, Toxicology	Kansas University Medical Center, 1980-82
Ph.D., Medicinal Chemistry	Kansas University, 1980
B.A., Chemistry	Benedictine College, 1974

PROFESSIONAL EXPERIENCE

2003-present	President and principal consultant, R&D Services, a pharmaceutical consulting firm
2002-2003	Chief Scientific Officer, XenoTech LLC
2000-2002	Senior Director, Group Leader early ADME/Drug Metabolism groups, Quintiles after acquisition from HMR
1987-1998	Group Leader, Scientist, Senior Associate Scientist, Senior Biochemist in Drug Metabolism at Hoechst Marion Roussel/Marion Merrell Dow/Marion Labs
1982-1987	Senior Research Scientist and Senior Scientist, Preclinical Drug Metabolism, Ciba- Geigy Corporation

SELECTED KEY ACCOMPLISHMENTS

- Starting in 2003, built a successful pharmaceutical consulting business, with 19 past and present clients from small and mid-size pharma and CROs.
- During this period, responsible for the clinical and/or preclinical ADME sections for three IND submissions and numerous project reports
- Lead the technical team at XenoTech which submitted a successful grant proposal for an NIH/NIDA sponsored Request for Proposal (RFP).
- Lead the transition of the early ADME and Drug Metabolism groups within Hoechst Marion Roussell to the corresponding contract service groups within Quintiles
- Lead early drug metabolism support for several high profile Drug Discovery programs in the areas of elastase inhibitors, H1/NK1, NK1/NK2 and 5HT receptor antagonists for Marion Merrell Dow and Hoechst Marion Roussell
- Project leader for all aspects of in vitro and clinical drug metabolism for an anti-psychotic drug in clinical development. (including protocol design, monitoring the in-life study and subsequent analysis, and report preparation for the human ADME study).

PRESIDENT AND PRINCIPAL CONSULTANT
tnt@rdservkc.com

CURRICULUM VITAE

SELECTED KEY ACCOMPLISHMENTS (continued)

- Authored the DMPK section for the NDA as well as a key drug interaction position paper for the same anti-psychotic drug in clinical development.
- Recipient of special achievement awards for technical excellence at Ciba-Geigy, Hoechst Marion Roussel, Quintiles and XenoTech.
- Invited podium speaker at recent ISSX and AAPS international meetings.
- Invited lecturer to the Medicinal Chemistry department at Kansas University.
- Adjunct professor, University of Kansas department of Medicinal Chemistry, part of a
- team teaching MedChem 790.

PROFESSIONAL ASSOCIATIONS

- American Association of Pharmaceutical Sciences (1986 to present)
- (General chair for 1997 regional meeting Session, Vice general chair for 1996 regional
- meeting, chair for PPDM section at May, 1991 regional meeting)
- International Society for the Study of Xenobiotics (1984 -present)
- American Chemical Society (1974 to present)
- Kansas City Discussion Group for Pharmaceutical Sciences, Founding Member and Treasurer (1990-1994)
- Central States Chapter of the Society of Toxicology (1987 to present)
- North Jersey Drug Metabolism Discussion Group: (Secretary, 1984-1986, Chair-elect and
- Chairman 1987 Annual Symposium

PUBLICATIONS

Authored 31 manuscripts, reviews or book chapters, 22 invited platform presentations and 46 abstracts presented at national meetings. Six most recent listed over, a complete list is available here.

R&D SERVICES
A Pharma Consulting Co.

DR. THOMAS N. THOMPSON WWW.RDSERVKC.COM

PRESIDENT AND PRINCIPAL CONSULTANT
tnt@rdservkc.com

CURRICULUM VITAE

MANUSCRIPTS/REVIEWS/BOOK CHAPTERS

1. Effect of MMX® mesalamine coadministration on the pharmacokinetics of amoxicillin, ciprofloxacin XR, metronidazole, and sulfamethoxazole: results from four randomized clinical trials. Pierce D, Corcoran M, Martin P, Barrett K, Inglis S, Preston P, Thompson TN, Willsie SK.. Drug Des Devel Ther. 2014 May 14;8:529-43.
2. Pharmacokinetics and tissue and tumor exposure of CP-31398, a p53-stabilizing agent, in rats. Kapetanovic IM, Muzzio M, McCormick DL, Thompson TN, Johnson WD, Horn TL, Mohammed A, Rao CV, Kopelovich L. Cancer Chemother Pharmacol. 2012 May;69(5):1301-6.
3. Pharmacokinetics, oral bioavailability, and metabolic profile of resveratrol and its dimethylether analog, pterostilbene, in rats. Kapetanovic IM, Muzzio M, Huang Z, Thompson TN, McCormick DL. Cancer Chemother Pharmacol. 2011 Sep;68(3):593-601.
4. The clinical significance of drug transporters in drug disposition and drug interactions, Thomas N. Thompson. In: Pharmacokinetics in Drug Development, Vol 3. Peter Bonate and Danny Howard, editors. Springer Verlag, 2010, chapter 13, pp 285-313.
5. Safety Testing of Drug Metabolites. Thomas N. Thompson, In: John E. Macor, editor: Annual Reports in Medicinal Chemistry, Vol 44, Chapter 22, Elsevier, The Netherlands: 2009, pp. 459-474.
6. Drug Metabolism In-vitro and In-vivo Results: How do These Data Support Drug Discovery? Thomas N. Thompson, in “Using Mass Spectrometry for Drug Metabolism” (Walter Korfmacher, ed.) CRC Press, Boca Raton, FL, 2005.